• Nivolumab treatment at doses of 3 mg/kg once every 2 weeks (Q2W), 240 mg Q2W, and 360 mg once every 3 weeks was well tolerated in the Chinese population, with no new safety signals identified.
the overall efficacy, safety, and PK of nivolumab have been extensively studied, these data were established in predominantly Caucasian populations. The safety and intensive PK of nivolumab flat-dose regimens (240 mg Q2W or 360 mg once every 3 weeks) have not been assessed in Chinese patients.
This single-center, open-label, phase I/II study assessed the safety and tolerability of nivolumab in Chinese adult patients with previously treated, advanced or recurrent NPC or other solid tumors. Secondary objectives were PK, immunogenicity, and preliminary antitumor activity.
There were no new safety signals for nivolumab in Chinese patients, and safety profiles were consistent with prior clinical studies ( Table 1) . Of 46 evaluable patients, 35 experienced TRAEs; there were no grade 4-5 TRAEs, and only two were grade 3 (asthenia, 3 mg/kg cohort; hypochloremia, 240 mg cohort). Two serious TRAEs occurred, a grade 4 hyponatremia (240 mg cohort) and an indeterminate grade pancreatitis and cerebellar hemorrhage (3 mg/kg cohort) that led to discontinuation.
Intensive PK profiles were characterized after first nivolumab dose and at steady state in all cohorts; PK data were compared with results from global patients and revealed no ethnic sensitivity at 3 mg/kg Q2W (Table 2) . At data cutoff, antidrug antibodies were detected in 1 of 41 patients tested (3 mg/kg cohort).
Among the 32 patients (70%) with NPC, the objective response rate was 13% (95% confidence interval [CI]: 4-29) and the disease control rate was 66% (95% CI: 47-81). The median follow-up duration was 7.5 months (range: 0.8-24.7 months), and median progression-free survival was 3.5 months (95% CI: 1. 8-5.5) .
In this pretreated group of patients with predominantly NPC, our study showed that the safety, tolerability, and PK (3 mg/kg) of nivolumab are similar in Chinese and global populations. Furthermore, promising antitumor activity of nivolumab in NPC suggests that further studies are warranted. Total treatment-related SAEs, n (%) Generic/Working Name Nivolumab
Trade Name Opdivo
Company Name Bristol-Myers Squibb Pharmaceuticals Ltd.
Drug Type Antibody

Drug Class
Immune therapy Table 3 .
DOSE ESCALATION TABLE
Cancer Types or Histologic Subtypes
Hepatocellular carcinoma, 2 Lung, non-small cell, 11 Nasopharyngeal carcinoma, 32 Not reported, 1
PRIMARY ASSESSMENT METHOD
Title
New assessment
Title Total patient population
Number of Patients Screened 51
Number of Patients Enrolled 51
Number of Patients Evaluable for Toxicity 46
Number of Patients Evaluated for Efficacy 46
Evaluation Method RECIST 1.1
Response Assessment PR n = 6 (13%)
Response Assessment SD n = 20 (43%)
Response Assessment PD n = 18 (39%)
Response Assessment OTHER n = 2 (4%)
Outcome Notes
Regarding "Response Assessment OTHER," responses could not be determined for these patients. Treatment-related pancreatitis and cerebellar hemorrhage in one patient led to discontinuation of study treatment.
ADVERSE EVENTS
SERIOUS ADVERSE EVENTS
ASSESSMENT, ANALYSIS, AND DISCUSSION
Completion Interim analysis, study ongoing (480 mg cohort recruiting)
Nivolumab is a human monoclonal antibody that targets the programmed death receptor-1 (PD-1) and has been approved for the treatment of various types of cancer in ≥60 countries [2]. Early-stage clinical trials of anti-PD-1 therapies have shown promising activity in recurrent or metastatic nasopharyngeal carcinoma (NPC), a common cancer in southeast Asia and North Africa [3, 4] , with objective response rates (ORRs) of 21%-34% [5] [6] [7] .
The overall efficacy, safety, and pharmacokinetics (PK) of nivolumab are based on clinical data from approximately 17,600 global (predominantly Caucasian) patients [8] [9] [10] [11] [12] [13] [14] [15] . The safety of nivolumab 3 mg/kg administered once every 2 weeks (Q2W) has been assessed in Chinese patients in the CheckMate 078 study (NCT2613507), leading to its approval for the treatment of nonsmall cell lung cancer in China [16] ; nivolumab 240 mg Q2W is approved in the U.S.
[2] and Japan [17] .
This study therefore aimed to assess the safety, tolerability, and PK of nivolumab in Chinese patients with previously treated, advanced or recurrent NPC or other solid tumors. Importantly, this is the first study to assess the safety and intensive PK of 240 mg and 360 mg flat-dose regimens in Chinese patients.
This was an open-label, single-center, phase I/II study (CheckMate 077; NCT02593786) of nivolumab monotherapy. The study comprised a dose evaluation phase (3 mg/kg Q2W, 60-minute intravenous [IV] infusion) and cohort expansion phase (3 mg/kg Q2W, flat dose 240 mg Q2W and 360 mg once every 3 weeks [Q3W]; 30-minute IV infusion) and consisted of a screening period (≤28 days), a treatment period (until disease progression or intolerable toxicities), and a follow-up period (≤100 days).
Included patients were Chinese adults (aged ≥18 years), Eastern Cooperative Oncology Group Performance Status 0 or 1, with histologically or cytologically confirmed solid tumors that were clinically advanced or recurrent, who had progressed after ≥1 prior line of systemic therapy. Exclusion criteria included central nervous system metastases, prior malignancy (except for nonmelanoma or certain in situ cancers, or complete remission ≥2 years), autoimmune disease, prior immunotherapy, active tuberculosis infection, pregnancy, or immunosuppressive agent treatment.
At data cutoff, 51 patients were enrolled, of whom 46 (90%) received ≥1 dose of study treatment and were evaluable for safety (Fig. 1) . Baseline patient characteristics are presented in Table 3 ; the median patient age was 48 years (range: 27-72 years), 67% (31) were male, and 28 (61%) had received >2 prior lines of systemic anticancer therapy. Forty-three patients (93%) had discontinued during the treatment period, mostly because of disease progression (35 patients, 76%), and only 1 patient because of study drug toxicity. Three patients (7%) discontinued because of adverse events (AEs) unrelated to nivolumab.
At data cutoff, median (range) duration of treatment was 11.7 (2.0-105.1) weeks for the 3 mg/kg cohort, 16.6 (2.0-98.7) weeks for the 240 mg cohort, and 24.1 (3.0-48.9) weeks for the 360 mg cohort. The median (range) cumulative dose per subject were 1,920.0 (240.0-11,520.0) mg and 2,880.0 (360.0-5,076.0) mg for the 240 mg and 360 mg cohorts, respectively, and 18.2 (3.0-152.3) mg/kg in the 3 mg/kg cohort.
No dose-limiting toxicities were observed during the dose evaluation phase (n = 8) or dose expansion phase. Incidence of treatment-related adverse events (TRAEs) was similar across cohorts (Table 1) . Overall, no new safety signals were identified, with safety profiles consistent with prior global studies and in line with a phase III study in Chinese patients (NCT02613507) [8] [9] [10] [11] [12] [13] [14] [15] [16] [18] [19] [20] . There were two grade ≥3 TRAEs: one grade 3 asthenia in the 3 mg/kg cohort and one grade 3 hypochloremia in the 240 mg cohort. Treatmentrelated serious adverse events were a grade 4 hyponatremia (240 mg cohort) and pancreatitis and cerebellar hemorrhage of indeterminate grade (one patient, 3 mg/kg cohort) that led to discontinuation of treatment. There were no incidences of death associated with nivolumab.
In terms of all-cause AEs, incidence of hypothyroidism was 30% in the 240 mg cohort (three patients each experienced a grade 1 or 2 event) and 55% in the 360 mg cohort (five patients with a grade 1 event and one patient with a grade 2 event) compared with no such reported events in the 3 mg/kg cohort. This most likely reflects the increased proportions of patients with NPC in the flat-dosing cohorts who had received prior radiotherapy.
Intensive PK profiles of nivolumab were characterized following a single dose (Cycle 1, Day 1) and multiple doses (3 mg/kg and 240 mg: Cycle 3, Day 1; 360 mg: Cycle 6, Day 1). Single-dose nivolumab resulted in rank-order differences in the mean serum concentration versus time profiles, with the highest mean concentrations observed for the 360 mg Q3W flat dose, followed by the 240 mg Q2W flat dose and the 3 mg/kg Q2W dose ( Fig. 2A) . PK parameters were assessed via noncompartmental analysis and showed similar rank-order relationships for the geometric mean area under the serum concentration-time curve for a dosing interval (AUC tau ), maximum serum concentration and concentration at the end of the dosing interval (Table 4) .
Steady state was reached by approximately Cycle 3 (Week 17: 3 mg/kg and 240 mg flat dose) or Cycle 6 (Week 16: 360 mg flat dose; Fig. 2C ). At steady state, the mean serum nivolumab concentration profiles over time were similar between the flat-dose cohorts and appeared lower for the 3 mg/kg cohort (Fig. 2B) . The geometric mean AUC tau for the 360 mg flat-dose cohort was approximately 41% and 72% higher than for the 240 mg flat-dose and 3 mg/kg cohorts, respectively. However, when normalized by dosing interval, the AUC tau values were comparable, indicating that the different dosing regimens yielded comparable average concentrations at steady state. The mean effective half-life varied between cohorts (521-752 hours, or 21.7-31.3 days) but was within AE5 days of the mean elimination half-life of 25 days reported previously [2] .
At 3 mg/kg, nivolumab exposure in Chinese patients was similar to that of patients in a global phase I study (NCT00730639), as demonstrated by a cross-study comparison (Table 2 ) [1] . These data are also in agreement with a recent phase I study of nivolumab in advanced solid tumors in Korean patients, in which PK data were shown to be comparable to U.S. and Japanese populations [21] .
Immunogenicity was assessed via antidrug antibody (ADA) status (Table 5) . Of 41 evaluable patients, only 1 patient (3 mg/kg cohort) was ADA positive after treatment. None of the patients were persistently ADA positive or neutralizing antibody positive.
Preliminary antitumor activity was assessed for patients with NPC tumors and for patients with all other solid tumors. Of 32 patients with NPC, 15 (47%) had a reduction in tumor burden from baseline following nivolumab treatment (Fig. 3) . Four patients (13%) achieved a partial response (two patients each, 3 mg/kg and 240 mg cohorts), and 17 (53%) had stable disease. The ORR and disease control rate (DCR) in this patient group were 13% (95% confidence interval [CI]: 4-29) and 66% (95% CI: 47-81), respectively (Table 6 ; Fig. 4) . Patients with other solid tumor types achieved an ORR of 14% and a DCR of 36%.
The median (range) follow-up duration for patients with NPC was 7.5 (0.8-24.7) months, with six patients (19%) having received nivolumab treatment for >1 year. Median progressionfree survival (PFS) was 3.5 months (95% CI: 1.8-5.5 months), and median overall survival (OS) was not reached. The 3-month PFS and OS rates were 64.2% (95% CI: 44.7-78.4) and 87.5% (95% CI: 70.0-95.1), respectively.
This study confirms the safety profile of nivolumab at 3 mg/kg in Chinese patients and is the first to report tolerability at flat doses of 240 mg and 360 mg in this population. Additionally, these data indicate that the PK of nivolumab monotherapy are ethnically insensitive. In this population of pretreated patients with advanced or recurrent disease, preliminary antitumor responses in NPC are encouraging; confirmation is required in a larger patient population. 
